pharmaphorum2d
Praluent not worth the price, finds study
Sanofi and Regeneron’s Praluent may still not be cost effective compared to other cholesterol-lowering drugs despite a recent price cut, a new study has claimed. The drug's high price point has ...
Regeneron: Strong Buy Rating Driven by Dupixent’s Growth and Promising Pipeline Developments
Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...
Beyond The Numbers: 18 Analysts Discuss Regeneron Pharmaceuticals Stock
Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $945.56, a high ...
pharmaphorum6d
Praluent approved to reduce CV risk in Europe
The European Commission has approved Sanofi and Regeneron’s Praluent for reducing cardiovascular risk in adults with established atherosclerotic CV disease (ASCVD), giving the drug another ...
Business Insider23d
Regeneron’s Mixed Eylea Sales and Competitive Challenges Prompt Neutral Rating
Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. Read More on REGN: Regeneron Pharmaceuticals NewsMORE Related Stocks ...
Benzinga.com29d
What Analysts Are Saying About Regeneron Pharmaceuticals Stock
Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators ...
Regeneron Pharmaceuticals, Inc. (REGN) Stock Forecasts
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, ...